Phase III trial of mocetinostat in combination with azacitidine as first-line therapy in patients with myelodysplastic syndromes.

Trial Profile

Phase III trial of mocetinostat in combination with azacitidine as first-line therapy in patients with myelodysplastic syndromes.

Planning
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2014

At a glance

  • Drugs Mocetinostat (Primary) ; Azacitidine
  • Indications Myelodysplastic syndromes
  • Focus Registrational; Therapeutic Use
  • Sponsors Mirati Therapeutics
  • Most Recent Events

    • 17 Mar 2014 Mirati Therapeutics plans to obtain a Special Protocol Assessment (SPA) from the US FDA for this potential registration trial in myelodysplastic syndromes, according to a Mirati media release.
    • 19 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top